Comparative Benchmarking
In the context of the broader market, DMAC competes directly with industry leaders such as LCTX and CADL. With a market capitalization of $369.16M, it holds a leading position in the sector. When comparing efficiency, DMAC's gross margin of N/A stands against LCTX's 99.00% and CADL's N/A. Such benchmarking helps identify whether DiaMedica Therapeutics Inc is trading at a premium or discount relative to its financial performance.
